Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer.[1] It may also be used to treat hypercalcemia (elevated blood calcium levels). It is typically formulated as its sodiumsaltibandronate sodium.
Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women.[3] In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis. Every participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug.
Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers.[4]
Adverse effectsEdit
In 2008, the U.S. Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint or muscle pain.[5] A study conducted by the American Society of Bone and Mineral Research concluded that long-term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the femur. [6] The drug also has been associated with osteonecrosis of the jaw, relatively rare but serious condition.[7]
Ibandronic acid is marketed under the trade names Boniva in the US, Bondronat in Europe, Bonviva in Asia, Bandrone in India, Ibandrix in Ecuador, Adronil in Pakistan, Bondrova in Bangladesh and Bonprove in Egypt, Fosfonat in Mexico.
ReferencesEdit
^Bauss F, Schimmer RC (March 2006). "Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis". Therapeutics and Clinical Risk Management. 2 (1): 3–18. PMC1661644. PMID 18360577.
^Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 523. ISBN9783527607495.
^"Boniva". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
^Sittig HB (2012). "Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate". Onkologie. 35 (6): 380–7. doi:10.1159/000338947. PMID 22722461. S2CID 8413102.
^"Information for Healthcare Professionals: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)". U.S. Food and Drug Administration. Retrieved 27 October 2010.
^Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. (American Society for Bone and Mineral Research) (November 2010). "Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research". Journal of Bone and Mineral Research. 25 (11): 2267–2294. doi:10.1002/jbmr.253. PMID 20842676. S2CID 15194275.; Lay summary in: . Journal of Bone and Mineral Research. 14 September 2010. Archived from the original on 9 April 2016. Retrieved 27 October 2010.
^(PDF). United Kingdom: The National Osteoporosis Society. Archived from the original (PDF) on 2017-06-17. Retrieved 2018-08-14.
^Tripathi KD (2013-09-30). Essentials of Medical Pharmacology (Seventh ed.). New Delhi: Jaypee Brothers Medical Publisher. ISBN9789350259375. OCLC 868299888.
External linksEdit
"Ibandronic acid". Drug Information Portal. U.S. National Library of Medicine.
ibandronic, acid, bisphosphonate, medication, used, prevention, treatment, osteoporosis, metastasis, associated, skeletal, fractures, people, with, cancer, also, used, treat, hypercalcemia, elevated, blood, calcium, levels, typically, formulated, sodium, salt,. Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis associated skeletal fractures in people with cancer 1 It may also be used to treat hypercalcemia elevated blood calcium levels It is typically formulated as its sodium salt ibandronate sodium Ibandronic acidClinical dataTrade namesBoniva Bonviva Bondronat othersAHFS Drugs comMonographLicense dataEU EMA by INN US DailyMed Ibandronate sodium US FDA Ibandronate sodiumPregnancycategoryAU B3Routes ofadministrationBy mouth intravenousATC codeM05BA06 WHO Legal statusLegal statusUS only EU Rx only In general Prescription only Pharmacokinetic dataBioavailability0 6 Protein binding90 9 to 99 5 concentration dependent MetabolismNilElimination half life10 to 60 hoursExcretionKidneyIdentifiersIUPAC name Hydroxy 1 hydroxy 3 methyl pentyl amino 1 phosphonopropyl phosphinateCAS Number114084 78 5 YPubChem CID60852IUPHAR BPS3059DrugBankDB00710 NChemSpider54839 YUNIIUMD7G2653WKEGGD08056 Yas salt D04486 YChEBICHEBI 93770ChEMBLChEMBL997 YPDB ligandBFQ PDBe RCSB PDB CompTox Dashboard EPA DTXSID5048340ECHA InfoCard100 214 537Chemical and physical dataFormulaC 9H 23N O 7P 2Molar mass319 231 g mol 13D model JSmol Interactive imageSMILES O P O O C O CCN CCCCC C P O O OInChI InChI 1S C9H23NO7P2 c1 3 4 5 7 10 2 8 6 9 11 18 12 13 14 19 15 16 17 h11H 3 8H2 1 2H3 H2 12 13 14 H2 15 16 17 YKey MPBVHIBUJCELCL UHFFFAOYSA N Y N Y what is this verify It was patented in 1986 by Boehringer Mannheim and approved for medical use in 1996 2 Contents 1 Medical uses 2 Adverse effects 3 Pharmacology 4 Brand names 5 References 6 External linksMedical uses EditIbandronate is indicated for the treatment and prevention of osteoporosis in post menopausal women 3 In May 2003 the U S Food and Drug Administration FDA approved Ibandronate as a daily treatment for post menopausal osteoporosis The basis for this approval was a three year randomized double blind placebo controlled trial women with post menopausal osteoporosis Every participant also received daily oral doses of calcium and 400IUs international units of vitamin D At the study s conclusion both doses significantly reduced the occurrence risk of new vertebral fractures by 50 52 percent when compared to the effects of the placebo drug Ibandronate is efficacious for the prevention of metastasis related bone fractures in multiple myeloma breast cancer and certain other cancers 4 Adverse effects EditIn 2008 the U S Food and Drug Administration FDA issued a communication warning of the possibility of severe and sometimes incapacitating bone joint or muscle pain 5 A study conducted by the American Society of Bone and Mineral Research concluded that long term use of bisphosphonates including Boniva may increase the risk of a rare but serious fracture of the femur 6 The drug also has been associated with osteonecrosis of the jaw relatively rare but serious condition 7 Pharmacology EditRelative potency 8 Bisphosphonate Relative potencyEtidronate 1Tiludronate 10Pamidronate 100Alendronate 100 500Ibandronate 500 1000Risedronate 1000Zoledronate 5000Brand names EditIbandronic acid is marketed under the trade names Boniva in the US Bondronat in Europe Bonviva in Asia Bandrone in India Ibandrix in Ecuador Adronil in Pakistan Bondrova in Bangladesh and Bonprove in Egypt Fosfonat in Mexico References Edit Bauss F Schimmer RC March 2006 Ibandronate the first once monthly oral bisphosphonate for treatment of postmenopausal osteoporosis Therapeutics and Clinical Risk Management 2 1 3 18 PMC 1661644 PMID 18360577 Fischer J Ganellin CR 2006 Analogue based Drug Discovery John Wiley amp Sons p 523 ISBN 9783527607495 Boniva The American Society of Health System Pharmacists Retrieved 3 April 2011 Sittig HB 2012 Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer focus on ibandronate Onkologie 35 6 380 7 doi 10 1159 000338947 PMID 22722461 S2CID 8413102 Information for Healthcare Professionals Bisphosphonates marketed as Actonel Actonel Ca Aredia Boniva Didronel Fosamax Fosamax D Reclast Skelid and Zometa U S Food and Drug Administration Retrieved 27 October 2010 Shane E Burr D Ebeling PR Abrahamsen B Adler RA Brown TD et al American Society for Bone and Mineral Research November 2010 Atypical subtrochanteric and diaphyseal femoral fractures report of a task force of the American Society for Bone and Mineral Research Journal of Bone and Mineral Research 25 11 2267 2294 doi 10 1002 jbmr 253 PMID 20842676 S2CID 15194275 Lay summary in JBMR Publishes ASBMR Task Force Report on Atypical Femoral Fractures Journal of Bone and Mineral Research 14 September 2010 Archived from the original on 9 April 2016 Retrieved 27 October 2010 Osteonecrosis of the jaw ONJ and drug treatments for osteoporosis PDF United Kingdom The National Osteoporosis Society Archived from the original PDF on 2017 06 17 Retrieved 2018 08 14 Tripathi KD 2013 09 30 Essentials of Medical Pharmacology Seventh ed New Delhi Jaypee Brothers Medical Publisher ISBN 9789350259375 OCLC 868299888 External links Edit Ibandronic acid Drug Information Portal U S National Library of Medicine Portal nbsp Medicine Retrieved from https en wikipedia org w index php title Ibandronic acid amp oldid 1179876723, wikipedia, wiki, book, books, library,
